Related by context. All words. (Click for frequent words.) 69 LymphoStat B Phase 66 GENASIS clinical 64 EXPLORE Xa 64 GetGoal Phase III 64 lorcaserin Phase 63 PRECISE Trial 63 APEX PD 63 SUCCEED trial 63 Bayer HealthCare Onyx Pharmaceuticals 62 recombinant PSMA vaccine 62 Phase lll 62 REVIVE TA 62 placebo controlled Phase 62 IMC #B 62 AP IMPACT Credibility 62 ALN VSP Phase 61 tramiprosate Alzhemed TM 61 Pivotal Phase 61 BRIM2 61 multicenter Phase 61 phase IIb clinical 61 Second Pivotal Phase 61 tribulations Groenveld 61 MKC# MT 61 BioSante LibiGel Phase III 61 EVIZON TM squalamine lactate 61 phase IIa clinical 61 GVAX R 61 CHAMPION PCI 60 alvespimycin 60 Phase Ib II 60 Phase Ib IIa 60 Thorough QT 60 treatment naive genotype 60 denosumab oncology 60 Phase III Pivotal 60 BRIM3 60 GVAX ® 60 initiate multicenter 60 Zerenex Phase 60 budesonide MMX Phase III 60 initiated Phase Ib 60 PSMA ADC 60 sapacitabine CYC# 60 pivotal bioequivalence 60 PANVAC VF 60 evaluating mipomersen 60 NABTT 60 MIST II 60 XL# SAR# 59 Phase #b/#a clinical 59 velafermin 59 generation URAT1 inhibitor 59 UVIDEM 59 phase IIb 59 including eniluracil ADH 59 LUX Lung 59 Initiated Phase 59 oral picoplatin 59 phase Ib 59 CEL SCI Phase III 59 recombinant biopharmaceutical 59 HCD# [002] 59 pharmacogenomic translational research 59 solid tumors ZYBRESTAT 59 dose escalation phase 59 AZX# Phase 59 dose escalation Phase 59 ABSORB clinical 59 R#/MEM # 59 confirmatory Phase 3 59 trastuzumab DM1 T DM1 59 novel VDA molecule 59 Phase IIIb clinical 59 phase Ib clinical 59 Huggins Cams Time 59 Allovectin 7 59 older NSAID diclofenac 59 Phase IIa trials 58 confirmatory clinical 58 imetelstat GRN#L 58 lintuzumab SGN 58 Phase Ib clinical 58 ThermoDox ® clinical 58 acyclovir Lauriad R 58 PREOS R 58 multicenter dose escalation 58 AIMM trial 58 Cloretazine ® 58 randomized controlled multicenter 58 relapsed MM 58 Dextofisopam Phase 2b 58 Phase IIIb 58 placebo controlled multicenter 58 assessing T DM1 58 multicenter Phase III 58 SinuNase ™ 58 STEALTH C 58 RELOVAIR ™ 58 rALLy 58 Phase 2a clinical trials 58 ENDEAVOR III 58 Zemplar Capsules 58 Phase #/#a 58 randomized controlled Phase 58 ALSYMPCA 58 MKC# 58 Initiate Phase 58 acai pill 58 ongoing Phase IIIb 58 initiate Phase 1b 58 Stimuvax R 58 bavituximab monotherapy trial 58 generation HCV protease 58 PEG PAL 58 candidate CRLX# 58 MADIT 58 cancer indications bafetinib 58 Phase 2b clinical 57 custirsen 57 oncolytic virus therapies 57 azilsartan medoxomil 57 Phase 2b kidney transplant 57 placebo controlled Phase III 57 evaluating satraplatin 57 Crofelemer budesonide foam 57 VEGFR2 inhibitor 57 CG# oncolytic virus 57 Orosi Mill project 57 clinical trials Archexin 57 ENDEAVOR IV 57 blinded randomized placebo controlled 57 Urocortin 2 57 HEPLISAV TM hepatitis B 57 TOLAMBA 57 brentuximab vedotin SGN 57 confirmatory Phase III 57 Qnexa TM 57 adecatumumab MT# 57 phase IIa 57 JunJing II 57 NeoPharm anticipates 57 registrational 57 ENGAGE AF TIMI 57 ANCHOR trial 57 Phase 1a clinical 57 Recurrent Glioblastoma 57 NSABP C 57 MEND CABG II 57 phase IIb study 57 DAC HYP 57 GALNS 57 PRIMO CABG 57 Syncria albiglutide 57 IIb clinical trial 57 systemic Phase 1b 57 Empatic ™ 57 Sulonex TM 57 VESTASYNC II trial 57 Acetavance TM intravenous acetaminophen 57 elotuzumab 57 Phase #b/#a 57 evaluating tivozanib 57 Randomized Phase II 57 APEX AMI 57 FORTIS M 57 Active Ulcerative Colitis 57 CDAD Clostridium difficile 57 MEND CABG 57 registrational trial 57 GLP toxicology studies 57 multicenter Phase II 57 OPT CHF 57 CYT# potent vascular disrupting 57 Phase 1a 57 BLOOM Behavioral modification 57 ongoing Phase 1b 57 TransVax ™ 56 HuLuc# 56 telomerase inhibitor drug 56 ENRICH trial 56 TEC #OL 56 fidaxomicin Phase 56 mg/m2 cohort 56 Custirsen 56 TASKi2 56 Saxagliptin 56 IIa clinical 56 initiate Phase Ib 56 registrational Phase 56 Luramist TM 56 evaluating Actimmune 56 zileuton IV 56 HRPC ovarian cancer 56 CAPACITY trials 56 budesonide foam 56 TransVax 56 HGS ETR1 mapatumumab 56 controlled multicenter 56 Exelixis XL# 56 double blinded randomized 56 Phase III registrational 56 IMPACT DCM 56 tolevamer 56 REVIVE Diabetes 56 Xcellerated T Cells 56 Prostate AdenoCarcinoma Treatment 56 COSIRA trial 56 evaluating tesamorelin 56 fostamatinib 56 Ophena TM 56 VALOR trial 56 commercialize CorMedix drug 56 LUMINATE 56 Phase IIb III 56 oral ridaforolimus 56 Fast Tracked Phase 56 NO# [002] 56 Omigard 56 bapineuzumab AAB 56 LibiGel Phase III 56 Phase III ThermoDox 56 forodesine 56 PREGNANT Study 56 Targretin capsules 56 FORTIS M trial 56 Exherin TM 56 MKC# MKC# PP 56 PORxin TM platforms 56 ragweed allergy immunotherapeutic 56 XOMA 3AB 56 Proellex TM 56 subcutaneous PRO 56 treatment naïve genotype 56 ToGA 56 CONQUER OB 56 JAK#/JAK# inhibitor CYT# 56 Phase III LibiGel 56 IV RSD# 56 IMPACT DCM clinical 56 TKB# 56 confirmatory pivotal 56 bile duct tumor 56 Phenoptin 56 HGS ETR1 56 Ultrafast Insulin 56 Randomized Phase 56 Phase II 56 #au Gavin Punch 56 multicenter randomized Phase 56 Testosterone MDTS ® 56 AAG geldanamycin analog 56 rALLy trial 56 Phase III TRIST 56 PLK1 SNALP 56 evaluating T DM1 56 lintuzumab 56 Inovio clinical 56 Phase 1b dose escalation 56 dimebon latrepirdine 56 intravenous RSD# 55 LymphoStat B belimumab 55 Phase 2a trial 55 drilling recompletions 55 rALLy clinical trial 55 Trastuzumab DM1 55 Dextofisopam 55 selectin antagonist 55 telomerase therapeutic 55 EQUIP OB 55 Testosterone MDTS R 55 products MKC# PP 55 Solazed 55 TELCYTA 55 delta opioid receptor 55 EDEMA3 55 serine protease inhibitor CU# 55 recurrent metastatic ovarian cancer 55 PFO migraine 55 Pivotal Phase III 55 Phase III clinical 55 Tarvacin Anti Cancer 55 oral calcitonin licensed 55 Protexia ® 55 squalamine 55 Phase IIB 55 initiate Phase 2b 55 albiglutide 55 includes TOLAMBA TM 55 sunitinib malate 55 Phase III placebo controlled 55 evaluating satraplatin plus 55 TransVax TM 55 Budesonide foam crofelemer 55 Allovectin 7 R 55 Phase 1b 55 transmucosal delivery system 55 European Sepsis Trial 55 BR.# 55 number NCT# ClinicalTrials.gov 55 midstage clinical 55 maximally tolerated dose 55 darapladib 55 ADVANCE PD 55 exploratory Phase IIa 55 Elagolix 55 studies evaluating satraplatin 55 ICON7 55 Selective Electrochemical Tumor Ablation 55 ONCONASE R 55 iii GTx 55 HGS ETR2 55 TOCOSOL Paclitaxel 55 CLIRS trial 55 fund BioSante LibiGel 55 lumiliximab 55 3 registrational trial 55 ACCLAIM COPD 55 Amoxicillin PULSYS Phase III 55 Liposomal Grb 2 55 dose cohort 55 PRESEPT 55 non nucleoside HCV 55 Dojack faces 55 Liraglutide Effect 55 purified inactivated vaccine 55 CATIE AD 55 phase IIb trial 55 Troxatyl 55 0 SHOTS OFF 55 Phase 1b clinical 55 denosumab oncology clinical trials 55 Ketotransdel 55 Twinrix 55 Phase IIa clinical 55 midstage trials 55 Shigamabs ® 55 wide receiver Kenbrell Thompkins 55 Evaluation Program CTEP 55 Phase #/#a trial 55 JZP 55 DEB# 55 AERx ® 55 DSMB recommended 55 double blinded placebo 55 RECORD1 55 TELINTRA R 55 PRECiSE 55 dose escalation clinical 55 JunJing III 55 Vicor anticipates 55 Commences Phase 54 Panzem R NCD 54 Telik logo TELINTRA 54 CholeraGarde R 54 ORACLE MS 54 ocrelizumab 54 VTEUs 54 GATTEX ® 54 next generation URAT1 54 rumpled dresser 54 im peramivir 54 VICTOR E1 54 regorafenib 54 include Ischemic Paraplegia 54 Anturol TM 54 vosaroxin 54 ganetespib 54 REGN# 54 dirucotide MBP# 54 Allovectin 7 ® 54 gastro intestinal inflammation 54 phase III ACCLAIM 54 dosing cohort 54 LAST FIVE TRADING SESSIONS 54 Phase 2b clinical trials 54 Gentamicin Surgical Implant 54 Telintra 54 SIMPADICO 54 CLARITY study 54 OLpur TM H2H 54 inhaled AAT 54 verdict elicited gasps 54 Phase III 54 successfully commercialize Iluvien 54 TEMSO 54 Motesanib 54 apricitabine ATC 54 CONSERV 54 celgosivir 54 Evoltra ® 54 myasthenia gravis Huntington 54 LabCorp conducts clinical 54 Phase III Psoriasis 54 BWagner Philadelphia 54 hide reddened eyes 54 Phase Ib 54 OvaRex ® MAb 54 IIa trial 54 THALOMID 54 cobiprostone 54 clinical trials SGN 54 APF# Phase 54 PEG SN# 54 evaluating Xcytrin 54 orally administered compounds 54 Cloretazine R 54 TG MV 54 samalizumab 54 metastatic renal cell 54 AeroLEF TM 54 BLP# Liposome Vaccine 54 Actilon 54 Phase #b/#a trial 54 Surfaxin LS 54 Albuferon albinterferon alfa 2b 54 Phase Ib clinical trials 54 cathepsin K inhibitor 54 AirBoss Announces 54 clinical trials Archexin ® 54 lomitapide 54 treats acute lymphoblastic 54 AMPAKINE CX# 54 candidate REP# 54 Xcytrin R 54 Urocidin 54 randomized Phase IIb 54 ENDEAVOR IV clinical 54 PREGNANT PROCHIEVE Extending GestatioN 54 hGH CTP Phase 54 Genz # 54 Phase IIb clinical trials 54 Hematide ™ 54 randomized Phase 2b 54 SinuNase TM 54 Phase III ADT 54 Commence Phase 54 AKT inhibitor 54 volociximab 54 Tykerb lapatinib 54 TBC# 54 opioid naive 54 APPRAISE 54 EMPHASIS HF trial 54 Canvaxin TM 54 catheter occlusion 54 severe hypercholesterolemia 54 rindopepimut 54 sulfonylurea glimepiride 54 Quinamed 54 Initiates Phase II 54 FirstService NASDAQ FSRV 54 By REBECCA BEITSCH 54 L BLP# 54 Corlux 54 Prodarsan R 54 anti botulism antibody 54 RSD# oral 54 Phase 54 OvaRex 54 ZFP Therapeutics 54 Combination REOLYSIN R 54 RGB # 54 budesonide MMX 54 Phase IIb trials 54 Quinamed R 54 HGS# 54 novel therapeutic antibodies 54 deforolimus 54 COR Diabetes 54 PRESEPT study 54 PF # [002] 54 tezampanel NGX# 54 Quirky chanteuses Florence 54 docetaxel Taxotere R 54 CURRENT OASIS 7 54 StemEx 54 clinical trials dacetuzumab SGN 54 agonistic human 54 PROMACTA CARES 54 Phase IIa clinical trials 54 XL# anticancer compounds 54 clinic automation LabPas 54 Acute myelogenous leukemia 53 Phase III confirmatory 53 EQUATE OB 53 Pre Exposure Prophylaxis 53 REMINYL ® 53 Omacetaxine 53 CURE AF 53 Phase III randomized controlled 53 trial evaluating Prochymal 53 Archexin 53 HOPE TOO 53 adecatumumab 53 dacetuzumab 53 prelicensure 53 bepotastine besilate nasal spray 53 PRE SURGE 53 STRIDE PD 53 Tesmilifene 53 Phase Ia 53 IMA# 53 compound INCB# 53 ACTIVE W 53 EmbraceAC 53 approved incretin mimetic 53 IL-#/# 53 MathMovesU scholarship 53 histrelin manufacturing marketing 53 XL# XL# XL# 53 REGENESIS Phase IIb 53 AIM HIGH 53 Advaxis Phase 53 EDEMA4 53 Pfizer Discontinues 53 tremelimumab 53 home eldercare evaluation 53 motesanib 53 Hedgehog antagonist 53 FluINsure 53 Phase 2a clinical 53 ovarian cancer chronic hepatitis 53 HEPLISAV ™ 53 evaluating nimotuzumab 53 drug figitumumab 53 Amigal TM 53 ROTATEQ 53 Bezielle 53 BENLYSTA ™ 53 Glufosfamide 53 ALISTA TM 53 Phase III HEAT 53 MAGE A3 ASCI 53 PROVENGE ® 53 Folfox 53 SYMMETRY trial 53 BLA filing 53 reduce serum phosphate 53 Daclizumab 53 Dyloject TM 53 AERAS-#/Crucell Ad# 53 tanespimycin 53 initiate Phase IIa 53 intravenous picoplatin include 53 Inc. Nasdaq ALSE 53 transgenically produced product 53 Medullary Thyroid Cancer 53 ORAL Solo 53 vaginally administered lidocaine 53 Stab stab 53 Pruvel 53 Phase Ib study 53 Phase IIA 53 Kosan dependence 53 designated HVTN 53 Phase 1b clinical trials 53 Stedivaze 53 Phase III multicenter 53 malignant mesothelioma Alfacell 53 Topical Interferon Alpha 2b 53 Nasdaq PGNX today 53 generation PNP inhibitor 53 class mGluR5 inhibitor 53 Avastin adjuvant 53 EURIDIS 53 ABSORB trial 53 CCR5 mAb 53 TNFerade ™ 53 hypoxia activated prodrug 53 sodium thiosulfate STS 53 Xanafide 53 Burkina Faso Gabon 53 oral prodrug 53 CALGB # [002] 53 TMC# C# 53 Calmare pain 53 kidney urologic 53 ENESTnd 53 PrevOnco ™ 53 Mtsare Khevi Field 53 pivotal Phase III 53 RiT Technologies Reports 53 oral proteasome inhibitor 53 StemEx R 53 lipoprotein lipase deficiency LPLD 53 zileuton injection 53 Successfully Completes Phase 53 Asentar TM 53 generation DACH Platinum 53 evaluating Nexavar 53 Lifeguard Collin Cobia 53 younger #-# gramonline.org 53 XL# XL# XL# XL# 53 bardoxolone 53 KNS # 53 Virulizin ® 53 Aryplase 53 BCIRG 53 prospective observational studies 53 CD# CEA 53 markets Testim ® 53 Phase 2b Clinical Trial 53 Canvaxin 53 Renal Cell Carcinoma RCC 53 systemic ALCL 53 5 HT2A inverse 53 HIV integrase inhibitor 53 DIRECT Trial 53 XP# XP# 53 relapsed refractory multiple myeloma 53 MARVEL Trial 53 ADMIRE HF 53 INTEGRILIN R eptifibatide Injection 53 visit http:/www.clinicaltrials.gov/ 53 TRAIL receptor antibody mapatumumab 53 Vitaxin 53 Lymphoseek ® 53 CCX# 53 RESTORE CLI trial 53 maribavir 53 endothelin antagonists 53 Qualified Person overseeing Lydian 53 granted Ortec 53 HealthStream Learning 53 SPIRIT FIRST 53 generation rotary VAD 53 sapacitabine 53 Diamyd ® 53 GENASIS trial 53 Ceflatonin R 53 oral deforolimus 53 VEGF Trap 53 Sorghum harvest 53 MoxDuo TM IR 53 torezolid phosphate 53 refractory AML 53 QNEXA ® 53 squamous non 53 OraTest R 53 telaprevir VX 53 Ereska 53 thorough QT 53 abysmal Shaiken 53 Q4 CY# 53 Dacogen injection 52 OncoVex 52 lead Aganocide compound 52 placebo controlled dose escalation 52 Initiates Phase III 52 forodesine hydrochloride 52 HIV AIDS neuropathic pain 52 omacetaxine mepesuccinate 52 PreCISe 52 Maximum Tolerated Dose MTD 52 talactoferrin 52 pivotal Phase 52 Ceplene/IL-2 52 resectable pancreatic cancer 52 AIDSVAX flunked 52 TRISENOX 52 Zerenex ™ 52 ARDIS 52 Katherine Heigl Mariska Hargitay 52 By JENI DODD 52 CMV vaccine 52 Emily Blunt shimmered 52 visilizumab 52 Tianyin achieved 52 TACI Ig 52 PMX # heptagonist 52 Planetwide Media My 52 multicenter randomized controlled 52 #nd EORTC NCI 52 initiated Phase 1b 52 naïve HCV 52 HuMax TAC 52 Thorough QT Study 52 Panzem ® 52 budesonide MMX ® 52 multicentre prospective 52 IND enabling 52 Indibulin 52 synthetic cannabinoid library 52 REVEAL Registry 52 glucokinase activator 52 investigational protease inhibitor 52 observational cohort 52 zileuton CR 52 Viprinex TM 52 TBC M4 52 PI3K/Akt pathway inhibitor 52 HCV SPRINT 52 CTA# Injection 52 evaluating bafetinib 52 Androxal TM 52 Genasense R oblimersen 52 platinum refractory 52 PRECISE trial 52 LibiGel BioSante 52 HPV cervical dysplasia 52 Zerenex 52 ragweed allergic children 52 Miikana 52 La. Protests Hark 52 sargramostim 52 TQ Micro 52 nucleoside tide 52 leading oral taxane 52 thrombin inhibiting aptamer 52 phase III SIMPADICO 52 Telatinib 52 Zemiva TM Trofex TM 52 LibiGel testosterone gel 52 Clinical Trials Update 52 incyclinide 52 solanezumab 52 oral PTH 52 metaglidasen 52 BHT DNA 52 SAR# [004] 52 initiate Phase IIb 52 LibiGel ® testosterone gel 52 Prestara 52 NATRECOR R 52 Phase 2b MATRIX 52 lenalidomide Revlimid R 52 Nuvelo Announces 52 CLIRS 52 Luveniq 52 selective S#P# receptor agonist 52 CR# vcMMAE 52 vaccine GMK 52 ospemifene 52 PHASE III 52 bevirimat Study 52 oral sapacitabine 52 orally administered inhibitor 52 low dose cytarabine 52 Vaxfectin R formulated 52 Pimavanserin 52 label multicenter randomized 52 MediGene focuses 52 generation rPA anthrax 52 ONTARGET 52 Randomized controlled 52 targeting miR 52 tramiprosate ALZHEMED TM 52 IMPACT IMmunotherapy 52 MOZOBIL 52 Harry Palmin President 52 QNEXA 52 riociguat 52 Pivotal Phase II 52 crizotinib PF # 52 OvaRex R 52 PC DAC Exendin 52 Oral NKTR 52 OncoVEX GM CSF 52 AVN# Phase 52 CB2 selective receptor agonist 52 TransVax tm 52 ritonavir boosted danoprevir 52 Azedra ™ 52 biliary tract cancer 52 FOLOTYN ® 52 Perifosine KRX 52 placebo controlled clinical 52 NOTE Subscriber 52 Kahalalide F 52 dependent kinase inhibitor 52 ancrod 52 TOCOSOL Camptothecin 52 Nanobody R 52 Phase 1b trial 52 evaluating carfilzomib 52 www.ingenuity.com 52 BrachySil TM 52 ACCEDE 52 candidate AQ4N 52 Celgosivir 52 rheumatoid arthritis thrombocytopenia 52 IPF CAPACITY 52 AVADO 52 Solectron pro forma 52 opioid induced bowel dysfunction 52 BRAF mutated 52 ABthrax TM raxibacumab 52 Aplidin R 52 investigational monoclonal antibody 52 EMPOWER ™ 52 midstage studies 52 Phase IIB clinical 52 Serada 52 Matrix Phase 2b 52 CRACM 52 cosmetic cosmeceutical products 52 PRIMO CABG2 52 ENABLE Phase 2 52 evaluating picoplatin 52 Q#IR 52 Phase 2b RESTORE CLI 52 Dr. Raafat Fahim 52 IND submission 52 Forodesine HCl 52 BY DAVID BERMAN 52 Truvada tablets 52 Phase IIIB IV 52 oral methylnaltrexone 52 CompX Reports 52 desvenlafaxine succinate 52 By Samantha Pidde 52 LOMUCIN TM 52 Genasense oblimersen sodium Injection 52 Nonperforming loans decreased 52 ZYBRESTAT fosbretabulin 52 viral kinetic 52 CCR9 antagonist 52 MYDICAR 52 anastrazole 52 castrate resistant prostate cancer 52 HCV polymerase 52 GRNVAC1 52 VITAL Trial 52 Multiple Ascending Dose 52 NVA# 52 Pharmos pipeline 52 Initiates Phase 52 phase 2a 52 confirmatory Phase IIIb 52 prednisone prednisolone plus 52 Pre RELAX AHF 52 NCT# ClinicalTrials.gov 52 isatoribine 52 Aldean Shelton 52 iv peramivir 52 orBec 52 GED aPC 52 HCA refiles 52 AdhTAP 52 HuCAL antibodies 52 E2F Decoy 52 ELACYT 52 modified REGENESIS Phase IIb 52 inflammatory autoimmune diseases 52 Trofex TM 52 LymphoStat B TM 52 STP McKay Thermal 52 SILENOR TM doxepin HCl 52 receiving chemoradiation therapy 52 BLOOM DM 52 EMPOWER Study 52 PHX# 52 RIO Diabetes 52 metastatic hormone refractory 52 Cand5 52 Genasense ® oblimersen 52 clinical pharmacology studies 52 Phase IIb REGENESIS 51 evaluable subjects 51 Begins Dosing 51 EOquin TM phase 51 LAB CGRP 51 sodium Injection 51 JM Dutton adds 51 CIMZIA ™ 51 refractory metastatic colorectal cancer 51 Other ImmunoGen collaborative 51 Independently Dyax 51 farletuzumab 51 Cloretazine R VNP#M 51 NP2 Enkephalin 51 Multicenter Randomized 51 evaluating Vectibix 51 recurrent metastatic 51 specified primary endpoint 51 ExCell study 51 basal cell carcinoma squamous 51 IND CTA 51 lupus renal disease 51 ponatinib 51 randomized Phase 51 controlled multicenter Phase 51 Asentar 51 axitinib 51 Bicifadine 51 Multicenter Automatic Defibrillator Implantation 51 Phase III VISTA 51 Novo TTF 51 Aurora kinase inhibitor 51 El Santuario gold 51 immunotherapeutic approaches 51 NSABP B 51 del Giocondo wife 51 HCV NS5B polymerase 51 Phase 2b trial 51 BLA submission 51 visit www.fiosinc.com 51 xtremepicks.com Profiles 51 MCSP respectively 51 ALN HPN 51 albiglutide currently 51 Alfimeprase 51 YONDELIS 51 deCODE AF TM 51 MAXY alpha 51 Alzhemed TM 51 ACTEMRA TM 51 Fossilized remnants 51 AQ4N 51 ILLUMINATE 51 IMC A# 51 MDS AML 51 Scopus Affiliation Identifier 51 resource delineation 51 website http:/www.celsion.com 51 glufosfamide 51 R vitespen 51 COMFORT II 51 landmark ATHENA 51 Phase III pivotal 51 Puricase PEG uricase 51 AVOREN 51 drug tesmilifene 51 LabCorp conducts clinical trials 51 Actor Ingo Rademacher 51 http:/www.vivus.com 51 Theratope 51 Dose escalation 51 Rezular 51 COSTAR II 51 TAXUS ATLAS 51 retinal vein occlusion induced 51 eldercare evaluation 51 Vicinium TM 51 #/#/# Cytokinetics Incorporated 51 REMURA 51 Biologic License Application BLA 51 MAA submission 51 aurora kinase inhibitor 51 Clinicaltrials.gov 51 oral RELISTOR 51 recurrent glioma 51 Tarceva TM 51 INCB# [001] 51 OVATURE 51 phase IIb III 51 JAK inhibitor 51 Immunotherapeutic 51 recurrent malignant glioma 51 ularitide 51 By Dave Ornauer 51 Phase IIb dose 51 R#/MEM 51 var arrContent = 51 R sorafenib tablets 51 Parkinson disease monogenic diseases 51 GeoVax HIV AIDS 51 Additionally BioMimetic Therapeutics 51 ALS #-# 51 Long Lesion 51 ® natalizumab 51 rhIGF-I/rhIGFBP-3 51 candidate brentuximab vedotin 51 Tesetaxel 51 Phase IIb kidney transplant 51 ZEGERID Capsules 51 ER CHOP 51 randomized discontinuation 51 Maxine Waters D Calif 51 eye socket ruptured bladder 51 metastatic colorectal 51 Phase IIb clinical 51 Oral Calcitonin 51 fidaxomicin Phase 3 51 eosinophilic asthma 51 trastuzumab DM1 51 Levacor 51 Solazed TM 51 oral FTY# 51 ONTAK 51 PROSTVAC VF 51 Shire velaglucerase alfa 51 EOquin TM 51 Epanova 51 multicenter multinational 51 novel antimitotic agent 51 KYNAPID 51 Huaiyin Power Plant 51 HDL Selective Delipidation 51 potent suppressor 51 overactive bladder AA# 51 Automotive Emission Canister 51 hoFH 51 Intervention Effectiveness 51 drug pipeline TAFA# 51 MARRIOTT REVENUES totaled 51 Currency Translation Adjustment 51 AcryMed Incorporated